Overview
Luminex provides xMAP technology, a multiplexed assay platform that enables simultaneous analysis of up to 500 analytes like cytokines, chemokines, and growth factors from minimal sample volumes. It combines proprietary microspheres, advanced fluidics, optics, and digital signal processing for high-throughput quantification in a single reaction. The technology supports applications in biomarker discovery, preclinical studies, inflammation, cancer, and metabolic disease research.
Frequently asked questions
- What analytes can Luminex xMAP technology measure?
- Luminex xMAP measures up to 500 analytes including cytokines, chemokines, growth factors, hormones, adipokines, proteins, and genes in a single low-volume sample.
- What are the key capabilities of Luminex platforms for high-throughput research?
- Luminex platforms offer multiplexing up to 96-500 analytes, small sample volumes, high sensitivity, automation, and compatibility with 384-well plates for rapid processing in biomarker discovery and preclinical studies.
- What industries or applications does Luminex serve?
- Luminex serves life sciences and pharma in areas like inflammation, cancer, metabolic disease, neurodegenerative disease, toxicity, immune response screening, and clinical diagnostics using flow cytometry-based bead analysis.